About Us
Klas Therapeutics Ltd, a spin-out from Ulster University, is at the forefront of innovative cancer treatment. We have developed KLAS-PDT, a groundbreaking technology designed to revolutionise the treatment of malignant melanoma.
Klas Therapeutics harnesses cutting-edge research and technological innovation to combat one of the deadliest forms of skin cancer. Our flagship technology, Klas-PDT, offers a breakthrough in cancer therapy by drastically reducing tumor size with minimal systemic side effects and scarring. We are dedicated to making cancer treatment more effective, affordable, and accessible, transforming patient care and outcomes.
Our Commitment to Innovation and Patient Care
Collaboration
At Klas Therapeutics Ltd, we believe in the power of collaboration and the importance of staying at the cutting edge of medical science.
Interdisciplinary Team
Our interdisciplinary team works closely with leading oncologists, researchers, and healthcare professionals to ensure that our treatments are not only innovative but also practical and effective in real-world clinical settings.
Core Values
We are a dedicated team, motivated to provide this first-in-class solution for malignant melanoma patients. We understand the pains of these patients and we are working to avail of a new therapy that is not only effective, but also, cost-effective.
Continuous Growth and Innovation
As we continue to grow and innovate, we remain dedicated to our core values of integrity, compassion, and scientific rigor.
Commitment to Excellence
Our commitment to excellence is reflected in how we intend to carry out our clinical trials, our continuous improvement processes, and unwavering focus on patient safety and satisfaction.
Making a Meaningful Impact
We strive to make a meaningful impact on the lives of those affected by malignant melanoma and other challenging cancers.
Key Offerings
Potential to offer targeted effective treatment options to melanoma patients with minimal scarring and systemic side effects.
Has the potential to be used as an independent treatment option or in combination with current standard of care.
Potential to be used at all stages in melanoma treatment, including local recurrence.
We are dedicated to contributing towards the UN Sustainable Development Goals: good health and well-being, reduced inequalities and responsible consumption and production.
Our lead compound has demonstrated efficacy against pancreatic, breast and prostate cancers.
Pioneering Patient-Centric Oncology Solutions
The Mission and Vision of
Klas Therapeutics
Our mission is to provide effective, affordable, and minimally invasive treatment options that significantly improve patient outcomes.
Led by a team of experts including Prof. Bridgeen Callan, Dr Poullette Oduor, Dr Rubeta Matin and and Prof. John Callan, we are committed to advancing cancer treatment through relentless research and development. We are also supported by top researchers and key opinion leaders in the melanoma industry to help us achieve our goal of availing KLAS-PDT to cancer patients.
With a vision rooted in scientific excellence and patient-centric solutions, Klas Therapeutics aims to lead the way in oncology innovations.
Klas Therapeutics Team
Learn more about the team of experts leading Klas Therapeutics and our pursuit to bring our pioneering technology to the market and patients.